Compare Campbell Soup Co. (CPB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs GSK plc — how do they compare? Campbell Soup Co. trades at $19.21 (market cap $5.78B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 15.9× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and GSK plc for 93 Days on average.
| CPB | GSK | |
|---|---|---|
Market Cap | $5.78B | $91.88B |
Volume | 11,705,427 | 7,730,529 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $61.18 |
52-Week Low | $18.90 | $43.24 |
Typical Hold Time | 98 Days | 93 Days |
Enterprise Value | $12.83B | $111.88B |
Dividend Yield | 5.16% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.37, up 2.49% today, but faces significant headwinds with a recent 36% dividend cut and bearish technical signals. The stock shows mixed earnings performance with two recent beats but a Q4 2026 miss, while fundamentals reveal modest revenue growth to $10.25B but declining net margins to 4.14%. Analyst sentiment remains cautious with only 3.45% buy ratings amid ongoing restructuring efforts.
The outlook remains challenging with weak FY2027 guidance and margin pressure, though current valuation (P/E 14.79) may attract value investors. Key risks include execution of $500M cost savings plan, competitive pressures, and consumer spending trends. The dividend yield near 5% post-cut offers income potential but requires careful monitoring of cash flow sustainability.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
